5,756 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by iSAM Funds UK Ltd

iSAM Funds UK Ltd acquired a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,756 shares of the biotechnology company’s stock, valued at approximately $1,116,000.

Several other institutional investors have also recently modified their holdings of BIIB. First Horizon Advisors Inc. raised its holdings in Biogen by 39.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 172 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 49 shares during the last quarter. CWM LLC raised its holdings in Biogen by 1.7% in the 2nd quarter. CWM LLC now owns 3,765 shares of the biotechnology company’s stock valued at $873,000 after acquiring an additional 62 shares during the last quarter. Grandfield & Dodd LLC raised its holdings in Biogen by 5.2% in the 3rd quarter. Grandfield & Dodd LLC now owns 1,261 shares of the biotechnology company’s stock valued at $244,000 after acquiring an additional 62 shares during the last quarter. Quintet Private Bank Europe S.A. raised its holdings in Biogen by 9.7% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 710 shares of the biotechnology company’s stock valued at $138,000 after acquiring an additional 63 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in Biogen by 1.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,122 shares of the biotechnology company’s stock valued at $1,419,000 after acquiring an additional 64 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wolfe Research assumed coverage on Biogen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Morgan Stanley downgraded Biogen from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $285.00 to $204.00 in a report on Thursday, October 31st. Citigroup assumed coverage on Biogen in a report on Thursday, November 14th. They set a “neutral” rating and a $190.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating and set a $292.00 price objective on shares of Biogen in a report on Monday, September 9th. Finally, Barclays dropped their price objective on Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday, October 31st. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $257.20.

Biogen Trading Down 0.9 %

NASDAQ BIIB opened at $157.78 on Friday. Biogen Inc. has a twelve month low of $153.62 and a twelve month high of $268.30. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The stock has a market cap of $22.99 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 1.52 and a beta of -0.08. The firm’s 50 day moving average price is $175.31 and its two-hundred day moving average price is $201.22.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.31. The firm had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.43 billion. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The business’s quarterly revenue was down 2.5% compared to the same quarter last year. During the same period last year, the company posted $4.36 EPS. Equities analysts anticipate that Biogen Inc. will post 16.45 EPS for the current year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.